Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Post Quarterly Sales of $49.74 Million

Wall Street brokerages forecast that Meridian Bioscience, Inc. (NASDAQ:VIVO) will post $49.74 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Meridian Bioscience’s earnings, with estimates ranging from $49.44 million to $50.03 million. Meridian Bioscience reported sales of $46.81 million during the same quarter last year, which indicates a positive year-over-year growth rate of 6.3%. The company is expected to issue its next earnings report on Wednesday, January 24th.

On average, analysts expect that Meridian Bioscience will report full-year sales of $49.74 million for the current financial year, with estimates ranging from $205.20 million to $220.11 million. For the next year, analysts expect that the firm will report sales of $214.47 million per share, with estimates ranging from $212.93 million to $216.01 million. Zacks’ sales averages are an average based on a survey of research firms that follow Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last released its earnings results on Thursday, November 9th. The company reported $0.15 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.15. The business had revenue of $49.70 million during the quarter, compared to the consensus estimate of $48.28 million. Meridian Bioscience had a net margin of 10.74% and a return on equity of 17.03%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.14 earnings per share.

A number of research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. Canaccord Genuity reissued a “hold” rating and issued a $14.00 price objective on shares of Meridian Bioscience in a research report on Friday, October 13th. Two investment analysts have rated the stock with a sell rating and four have issued a hold rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $11.50.

Meridian Bioscience (NASDAQ VIVO) traded up $0.40 during trading on Thursday, reaching $15.10. 337,800 shares of the company were exchanged, compared to its average volume of 250,971. The company has a market capitalization of $645.19, a P/E ratio of 29.61 and a beta of 0.90. Meridian Bioscience has a 1-year low of $10.75 and a 1-year high of $17.50. The company has a current ratio of 5.85, a quick ratio of 4.04 and a debt-to-equity ratio of 0.30.

Several institutional investors and hedge funds have recently made changes to their positions in the company. UBS Asset Management Americas Inc. grew its position in shares of Meridian Bioscience by 0.7% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 13,091 shares of the company’s stock valued at $206,000 after acquiring an additional 92 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Meridian Bioscience by 0.5% during the 2nd quarter. PNC Financial Services Group Inc. now owns 103,882 shares of the company’s stock worth $1,635,000 after buying an additional 485 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in shares of Meridian Bioscience by 1.1% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 115,208 shares of the company’s stock worth $1,815,000 after buying an additional 1,294 shares during the last quarter. Advisor Group Inc. lifted its stake in shares of Meridian Bioscience by 24.9% during the 2nd quarter. Advisor Group Inc. now owns 7,720 shares of the company’s stock worth $122,000 after buying an additional 1,537 shares during the last quarter. Finally, Thrivent Financial For Lutherans lifted its stake in shares of Meridian Bioscience by 8.0% during the 2nd quarter. Thrivent Financial For Lutherans now owns 25,520 shares of the company’s stock worth $402,000 after buying an additional 1,880 shares during the last quarter. 86.82% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Post Quarterly Sales of $49.74 Million” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.themarketsdaily.com/2018/01/11/brokerages-anticipate-meridian-bioscience-inc-vivo-will-post-quarterly-sales-of-49-74-million.html.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply